Puma Biotechnology lifts 2026 revenue outlook; alisertib Phase II updates

Puma Biotechnology raised its 2026 revenue outlook, citing strong NERLYNX domestic and international sales. The company also said alisertib Phase II trials in breast and lung cancer showed promising efficacy in biomarker subgroups, with expanded enrollment and more data expected later in 2026.